glp 1 agonist trials The transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award | Current Medicine Clinical Outcomes with GLP-1 Receptor
Description
The protective effects of liraglutide against A-induced neurotoxicity in neuroblastoma cells are attributed to the activation of the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, as evidenced by the increased phosphorylation of Akt and the altered expression of the apoptosis-related proteins Bcl-2/Bax, and cytochrome c [49]
The practical takeaway is that high-polyphenol EVOO is best understood as a metabolic tool within a whole-diet context, not as a standalone weight-loss agent
The dual agonist approach represented by tirzepatide demonstrates that activating multiple complementary pathways produces superior results to targeting a single pathway, even when that single pathway works quite well on its own
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
Do D et al
Liraglutide is the only GLP-1 receptor agonist indicated for use in children (10 years of age) with type 2 diabetes (10)
